Omeros Narrows Losses, Narsoplimab FDA Decision Pushed to December

TL;DR

**OMER's cost-cutting is good, but the narsoplimab FDA delay and zaltenibart pause mean more uncertainty and a longer wait for significant upside.**

AI Summary

Omeros Corporation reported a net loss of $25.4 million for the three months ended June 30, 2025, a significant improvement from the $56.0 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $58.9 million, down from $93.2 million in 2024. This improvement was driven by a substantial reduction in research and development expenses, which decreased from $45.3 million in Q2 2024 to $22.0 million in Q2 2025, and selling, general and administrative expenses, which fell from $13.8 million to $10.3 million over the same period. The company's cash and cash equivalents declined from $3.4 million at December 31, 2024, to $1.9 million at June 30, 2025, while short-term investments decreased from $86.7 million to $26.8 million. A key strategic development is the FDA's extended PDUFA date for narsoplimab in TA-TMA to December 26, 2025, following a resubmission in March 2025. Omeros also submitted a Marketing Authorization Application for narsoplimab in the EU in June 2025, with an opinion expected in mid-2026. However, the company temporarily paused its Phase 3 clinical development program for zaltenibart in PNH due to capital availability considerations, prioritizing other programs.

Why It Matters

Omeros's narrowed net loss and reduced operating expenses are positive signs for investors, indicating improved cost management. However, the delay in the FDA decision for narsoplimab to December 26, 2025, introduces continued regulatory uncertainty, which could impact investor sentiment and the company's stock price. The temporary pause of the zaltenibart Phase 3 program due to capital constraints highlights ongoing financial pressures, potentially affecting future revenue streams and competitive positioning against larger biopharmaceutical companies. Employees and customers are directly impacted by the success of narsoplimab, as approval would mean a new treatment option and potential job security. The broader market watches these regulatory milestones closely for shifts in the competitive landscape for complement-mediated disease treatments.

Risk Assessment

Risk Level: high — The company's cash and cash equivalents decreased from $3.4 million to $1.9 million, and short-term investments from $86.7 million to $26.8 million, indicating a significant reduction in liquidity. The temporary pause of the Phase 3 clinical development program for zaltenibart in PNH due to capital availability further underscores financial constraints and delays potential revenue generation from this candidate.

Analyst Insight

Investors should monitor the FDA's decision on narsoplimab closely, as approval could significantly de-risk the stock. However, given the capital constraints and the pause in the zaltenibart Phase 3 program, new investments should be approached with caution, focusing on the company's ability to secure additional funding and manage its burn rate effectively.

Financial Highlights

total Assets

$200.6M

net Income

-$25.4M

cash Position

$1.9M

Key Numbers

• $25.4M — Net loss for Q2 2025 (Reduced from $56.0M in Q2 2024)
• $58.9M — Net loss for H1 2025 (Reduced from $93.2M in H1 2024)
• $22.0M — Research and development expenses Q2 2025 (Decreased from $45.3M in Q2 2024)
• $1.9M — Cash and cash equivalents at June 30, 2025 (Decreased from $3.4M at Dec 31, 2024)
• $26.8M — Short-term investments at June 30, 2025 (Decreased from $86.7M at Dec 31, 2024)
• December 26, 2025 — Extended PDUFA date for narsoplimab (Originally September 25, 2025)
• 68,055,826 — Outstanding shares of common stock (As of August 12, 2025)
• $228.7M — Total shareholders' deficit at June 30, 2025 (Increased from $182.6M at Dec 31, 2024)

Key Players & Entities

• Omeros Corporation (company) — registrant
• FDA (regulator) — U.S. Food and Drug Administration
• EMA (regulator) — European Medicines Agency
• narsoplimab (company) — lead product candidate
• zaltenibart (company) — product candidate
• OMIDRIA (company) — former commercial ophthalmology product
• NIDA (regulator) — National Institute on Drug Abuse
• MASP-2 (company) — target of narsoplimab and OMS1029
• MASP-3 (company) — target of zaltenibart
• OMS527 (company) — PDE7 inhibitor program

FAQ

Risk Factors

• Deteriorating Cash Position and Liquidity Concerns [high — financial]: Cash and cash equivalents decreased from $3.4 million at December 31, 2024, to $1.9 million at June 30, 2025. Short-term investments also saw a significant drop from $86.7 million to $26.8 million in the same period. This sharp decline in liquid assets, coupled with a substantial shareholders' deficit of $228.7 million, raises concerns about the company's ability to fund ongoing operations and strategic initiatives, potentially impacting future development programs.
• Paused Clinical Development Due to Capital Constraints [high — operational]: The company temporarily paused its Phase 3 clinical development program for zaltenibart in PNH due to capital availability considerations. This decision highlights the direct impact of financial constraints on strategic execution and the prioritization of other programs, potentially delaying or jeopardizing the development of key pipeline assets.
• Extended PDUFA Date and EU MAA Uncertainty [medium — regulatory]: The FDA's PDUFA date for narsoplimab in TA-TMA has been extended to December 26, 2025, following a resubmission. Additionally, while a Marketing Authorization Application was submitted in the EU in June 2025, an opinion is not expected until mid-2026. These extended timelines introduce uncertainty and delay potential market entry for a critical drug candidate.
• Increasing Debt Load [medium — financial]: Total debt has increased, with convertible senior notes and term debt appearing in both current and non-current liabilities. Specifically, convertible senior notes, net, increased from $97.2 million to $160.5 million (current + non-current), and term debt, net, increased from $90.4 million to $87.3 million (current + non-current) between December 31, 2024, and June 30, 2025. This growing debt burden adds financial pressure.
• Significant Shareholders' Deficit [medium — financial]: The company reported a total shareholders' deficit of $228.7 million as of June 30, 2025, an increase from $182.6 million at the end of 2024. This negative equity position indicates that liabilities exceed assets, a persistent financial weakness.

Industry Context

The biotechnology sector, particularly companies focused on rare diseases and complex therapeutic areas like Omeros, faces intense competition and high R&D costs. Success is heavily reliant on regulatory approvals and successful clinical trials. Companies often operate with significant cash burn and rely on external financing or partnerships to fund development, making pipeline progression and market access critical.

Regulatory Implications

The extended PDUFA date for narsoplimab and the ongoing review process in the EU highlight the stringent and lengthy nature of drug approvals. Delays can significantly impact financial projections and competitive positioning. The company must navigate complex regulatory pathways while managing the financial implications of these extended timelines.

What Investors Should Do

1. Monitor cash burn and liquidity closely.
2. Track narsoplimab's regulatory progress in the US and EU.
3. Assess the impact of increased debt on financial flexibility.
4. Evaluate the company's strategy for managing capital constraints.

Key Dates

• 2025-12-26: Extended PDUFA date for narsoplimab in TA-TMA — This extension provides more time for FDA review but also delays potential market approval for a key drug candidate.
• 2025-06-30: Submitted Marketing Authorization Application for narsoplimab in the EU — Represents a significant step towards potential market access in Europe for narsoplimab.
• 2025-03-01: Resubmitted application for narsoplimab to FDA — This resubmission was a prerequisite for the extended PDUFA date and is crucial for potential US approval.
• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing reduced net loss but also a significant decrease in cash and investments.
• 2024-09-25: Original PDUFA date for narsoplimab in TA-TMA — The extension from this date indicates a longer-than-expected review process by the FDA.

Glossary

PDUFA date

Prescription Drug User Fee Act date, which is the date by which the FDA has agreed to make a regulatory decision on a new drug application. (The extension of this date for narsoplimab directly impacts the company's timeline for potential revenue generation from this drug.)

TA-TMA

Transplant-Associated Thrombotic Microangiopathy, a serious complication that can occur after stem cell transplantation. (This is the indication for which narsoplimab is seeking FDA approval, representing a key market opportunity for Omeros.)

PNH

Paroxysmal Nocturnal Hemoglobinuria, a rare blood disorder. (Zaltenibart is being developed for PNH, and the pause in its Phase 3 trial highlights the company's financial constraints.)

Shareholders' deficit

A situation where a company's total liabilities exceed its total assets, resulting in a negative net worth. (Omeros has a significant and growing shareholders' deficit, indicating a weak equity position.)

Convertible senior notes

Debt securities that can be converted into a predetermined amount of the issuer's equity. (The company has issued and carries significant amounts of convertible senior notes, impacting its debt structure and potential future dilution.)

Year-Over-Year Comparison

Compared to the prior year, Omeros Corporation has significantly reduced its net loss for both the three and six months ended June 30, 2025, primarily due to substantial cuts in R&D and SG&A expenses. However, this cost reduction has been accompanied by a sharp decline in cash and short-term investments, and an increase in total shareholders' deficit. New risks have emerged related to increased debt, including convertible senior notes, and the strategic decision to pause a Phase 3 trial due to capital availability, underscoring ongoing financial pressures despite improved operational loss figures.

Key Financial Figures

• $0.01 — h registered) Common Stock, par value $0.01 per share OMER The Nasdaq Stock Mar

Filing Documents

• omer20250630_10q.htm (10-Q) — 1518KB
• ex_822300.htm (EX-31.1) — 12KB
• ex_822301.htm (EX-31.2) — 13KB
• ex_822302.htm (EX-32.1) — 6KB
• ex_822303.htm (EX-32.2) — 6KB
• 0001437749-25-026933.txt ( ) — 8671KB
• omer-20250630.xsd (EX-101.SCH) — 82KB
• omer-20250630_def.xml (EX-101.DEF) — 571KB
• omer-20250630_lab.xml (EX-101.LAB) — 447KB
• omer-20250630_pre.xml (EX-101.PRE) — 598KB
• omer-20250630_cal.xml (EX-101.CAL) — 54KB
• omer20250630_10q_htm.xml (XML) — 1516KB

— Financial Information

Part I — Financial Information 5 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations and Comprehensive Loss 6 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

— Other Information

Part II — Other Information 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Default Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 25

Signatures

Signatures 26 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS OMEROS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 1,904 $ 3,400 Short-term investments 26,840 86,732 OMIDRIA contract royalty asset 28,221 29,083 Receivables 6,276 7,739 Prepaid expense and other assets 6,406 7,166 Total current assets 69,647 134,120 OMIDRIA contract royalty asset, non-current 114,735 124,266 Right of use assets 12,894 14,961 Property and equipment, net 2,239 2,678 Restricted investments 1,054 1,054 Total assets $ 200,569 $ 277,079 Liabilities and shareholders' deficit Current liabilities: Accounts payable $ 8,838 $ 5,905 Accrued expenses 26,277 26,005 OMIDRIA royalty obligation 19,596 20,645 Convertible senior notes, net 17,017 — Term debt — 21,000 Share-settled liability 7,627 — Lease liabilities 6,148 5,971 Total current liabilities 85,503 79,526 OMIDRIA royalty obligation, non-current 178,082 195,612 Convertible senior notes, non-current, net 63,474 97,178 Term debt, non-current, net 87,313 69,405 Lease liabilities, non-current 10,381 13,466 Other accrued liabilities, non-current 4,501 4,501 Commitments and contingencies (Note 10) Shareholders' deficit: Preferred stock, par value $ 0.01 per share, 20,000,000 shares authorized; none issued and outstanding at June 30, 2025 and December 31, 2024. — — Common stock, par value $ 0.01 per share, 150,000,000 shares authorized at June 30, 2025 and December 31, 2024; 60,022,332 and 58,044,465 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. 599 580 Additional paid-in capital 739,945 727,156 Accumulated deficit ( 969,229 ) ( 910,345 ) Total shareholders' deficit ( 228,685 ) ( 182,609 ) Total liabilities and share

View Full Filing

View this 10-Q filing on SEC EDGAR